Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial

Efficacy of lenalidomide was investigated in 103 patients with relapsed/refractory chronic lymphocytic leukemia (CLL) treated on the prospective, multicenter randomized phase-II CLL-009 trial. Interphase cytogenetic and mutational analyses identified TP53 mutations, unmutated IGHV, or del(17p) in 36...

Descripción completa

Detalles Bibliográficos
Autores principales: Bühler, A, Wendtner, C-M, Kipps, T J, Rassenti, L, Fraser, G A M, Michallet, A-S, Hillmen, P, Dürig, J, Gregory, S A, Kalaycio, M, Aurran-Schleinitz, T, Trentin, L, Gribben, J G, Chanan-Khan, A, Purse, B, Zhang, J, De Bedout, S, Mei, J, Hallek, M, Stilgenbauer, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817104/
https://www.ncbi.nlm.nih.gov/pubmed/26967821
http://dx.doi.org/10.1038/bcj.2016.9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817104/
https://www.ncbi.nlm.nih.gov/pubmed/26967821
http://dx.doi.org/10.1038/bcj.2016.9

Ejemplares similares